Oral propranolol for the treatment of hemangiomas in high-risk infants: safety and cost analysis of outpatient-initiated therapy
Oral propranolol treatment for high-risk infantile hemangiomas starting from the outpatient setting is associated with few adverse reactions and significantly reduced treatment costs. It is worthy of broader application in hospitals without dermatology wards.
Authors
- Jibin Li (ORCID: https://orcid.org/0000-0001-7632-3648)
- Rina Su (ORCID: https://orcid.org/0000-0003-4578-2993)
- Hui Lü (ORCID: https://orcid.org/0000-0001-5919-8259)
- Yang Gu (ORCID: https://orcid.org/0000-0002-6584-7216)
- Ting Zhang (ORCID: https://orcid.org/0000-0001-9391-8926)
- Wei Li (ORCID: https://orcid.org/0000-0001-7056-1290)
- Hua Qian
- Cui Hu
- Yingying Qian (ORCID: https://orcid.org/0000-0002-9075-1574)
- Bo Wu
- YaFen Wu
Institutions
- Capital Medical University (CN)
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- Soochow University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2024-09-13
- DOI
- https://doi.org/10.3389/fmed.2024.1439449
- Citations
- 3
- Primary Topic
- Vascular Malformations and Hemangiomas
- Type
- article
- Field-Weighted Citation Impact
- 1.72
Funders
- Soochow University